Correvio Pharma Corp.
https://correvio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Correvio Pharma Corp.
Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
Cryptic Terran Licences Advanced CNS Assets From Sanofi
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
How Organon Expects To Steer Its Women’s Health Engine In India
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- ADVANZ PHARMA Corp. Limited
- Cardiome Pharma Corp. (CRME)
- Cardiome Development AG
- Correvio LLC (Iroko Cardio LLC)